Difference between revisions of "Filanesib (ARRY-520)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "http://www.cancer.gov" to "https://www.cancer.gov") |
|||
| (6 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
| − | =Mechanism of action= | + | ==Mechanism of action== |
| − | From the [ | + | From the [https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=546990 NCI Drug Dictionary]: A synthetic, small molecule targeting the kinesin spindle protein (KSP) with potential antineoplastic activity. KSP inhibitor ARRY-520 specifically inhibits KSP (kinesin-5 or Eg5), resulting in activation of the spindle assembly checkpoint, induction of cell cycle arrest during the mitotic phase, and consequently cell death in tumor cells that are actively dividing. |
| − | [[Category: | + | ==Also known as== |
| − | [[Category: | + | *'''Code name:''' ARRY-520 |
| + | |||
| + | [[Category:Drugs]] | ||
| + | [[Category:Intravenous medications]] | ||
[[Category:KSP inhibitors]] | [[Category:KSP inhibitors]] | ||
| − | [[Category:Investigational]] | + | [[Category:Investigational drugs]] |
| + | [[Category:Stub]] | ||
Latest revision as of 20:20, 27 June 2024
Mechanism of action
From the NCI Drug Dictionary: A synthetic, small molecule targeting the kinesin spindle protein (KSP) with potential antineoplastic activity. KSP inhibitor ARRY-520 specifically inhibits KSP (kinesin-5 or Eg5), resulting in activation of the spindle assembly checkpoint, induction of cell cycle arrest during the mitotic phase, and consequently cell death in tumor cells that are actively dividing.
Also known as
- Code name: ARRY-520